STAT Plus: The tables are turned: Chinese regulator scolds a U.S. company for drug-manufacturing problems
The shoe is on the other foot, so to speak.
For the past few years, the Food and Drug Administration has tried harder to scrutinize Chinese pharmaceutical suppliers over widespread quality control concerns. Now, though, a Chinese government agency has found problems with a U.S. company that does contract manufacturing work for Bristol Myers Squibb (BMY) and, as a result, shipment of a key product to China has been suspended.
Continue to STAT Plus to read the full story…
